Financial reports
10-Q
2015 Q1
Quarterly report
30 Apr 15
10-K
2014 FY
Annual report
26 Feb 15
10-Q
2014 Q3
Quarterly report
30 Oct 14
10-Q
2014 Q2
Quarterly report
31 Jul 14
10-Q
2014 Q1
Quarterly report
1 May 14
10-K
2013 FY
Annual report
3 Mar 14
10-Q
2013 Q3
Quarterly report
4 Nov 13
10-Q
2013 Q2
Quarterly report
7 Aug 13
10-Q
2013 Q1
Quarterly report
7 May 13
Current reports
8-K
Completion of Acquisition or Disposition of Assets
23 Jun 15
8-K
Entry into a Material Definitive Agreement
6 May 15
8-K
Synageva Biopharma Reports First Quarter 2015 Financial Results and Provides General Business Updates
29 Apr 15
8-K
Synageva Biopharma Reports 2014 Full Year Financial Results
26 Feb 15
8-K
Entry into a Material Definitive Agreement
9 Feb 15
8-K
Entry into a Material Definitive Agreement
2 Feb 15
8-K
Synageva Biopharma Announces a 2.5 Million Share Proposed Public Offering of Its
7 Jan 15
8-K
Synageva Biopharma Reports Third Quarter 2014 Financial Results
30 Oct 14
8-K
Synageva Biopharma Appoints Robert Bazemore As Chief Operating Officer
22 Sep 14
8-K
Departure of Directors or Certain Officers
9 Sep 14
Registration and prospectus
15-12G
Securities registration termination
6 Jul 15
25-NSE
Exchange delisting
23 Jun 15
S-8 POS
Registration of securities for employees (post-effective amendment)
23 Jun 15
S-8 POS
Registration of securities for employees (post-effective amendment)
23 Jun 15
S-8 POS
Registration of securities for employees (post-effective amendment)
23 Jun 15
S-8 POS
Registration of securities for employees (post-effective amendment)
23 Jun 15
S-8 POS
Registration of securities for employees (post-effective amendment)
23 Jun 15
S-8 POS
Registration of securities for employees (post-effective amendment)
23 Jun 15
S-8 POS
Registration of securities for employees (post-effective amendment)
23 Jun 15
S-8 POS
Registration of securities for employees (post-effective amendment)
23 Jun 15
Proxies
DEF 14A
Definitive proxy
28 Apr 15
PRE 14A
Preliminary proxy
14 Apr 15
DEFA14A
Additional proxy soliciting materials
20 May 14
DEF 14A
Definitive proxy
23 Apr 14
DEF 14A
Definitive proxy
22 Apr 13
DEF 14A
Definitive proxy
27 Apr 12
DEF 14A
Definitive proxy
16 Mar 10
DEF 14A
Definitive proxy
29 Apr 08
DEF 14A
Definitive proxy
13 Jul 07
DEFA14A
Additional proxy soliciting materials
24 May 06
Other
CT ORDER
Confidential treatment order
24 Jun 15
CORRESP
Correspondence with SEC
8 Jun 15
UPLOAD
Letter from SEC
4 Jun 15
UPLOAD
Letter from SEC
3 Jun 15
CT ORDER
Confidential treatment order
31 Dec 14
CT ORDER
Confidential treatment order
24 Jul 14
CT ORDER
Confidential treatment order
31 Mar 14
UPLOAD
Letter from SEC
21 Aug 13
CORRESP
Correspondence with SEC
9 Aug 13
CORRESP
Correspondence with SEC
10 Jul 13
Ownership
SC 13G/A
Synageva Biopharma Corp
16 Feb 16
3
Initial statement of insider ownership
29 Jun 15
SC 13D/A
Synageva Biopharma Corp
24 Jun 15
4
JULIAN BAKER
23 Jun 15
4
Chris Heberlig
23 Jun 15
4
Sanj K Patel
23 Jun 15
4
Stephen R Biggar
23 Jun 15
4
Glen Williams
23 Jun 15
4
CARSTEN BOESS
23 Jun 15
4
Barry D Quart
23 Jun 15